Trial Profile
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Entinostat (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ENCORE 603
- Sponsors Syndax Pharmaceuticals
- 17 Aug 2022 Status changed from active, no longer recruiting to completed.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 07 Mar 2019 Primary endpoint of duration of Progression-free Survival has not been met, according to a Syndax Pharmaceutical media release.